No connection

Search Results

ABBV vs APLS

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
APLS
Apellis Pharmaceuticals, Inc.
BEARISH
Price
$18.94
Market Cap
$2.42B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
APLS
105.22
Forward P/E
ABBV
15.42
APLS
-77.94
P/B Ratio
ABBV
-146.66
APLS
6.48
P/S Ratio
ABBV
6.5
APLS
2.41
EV/EBITDA
ABBV
15.27
APLS
42.6

Profitability

Gross Margin
ABBV
71.46%
APLS
60.34%
Operating Margin
ABBV
35.5%
APLS
-25.58%
Profit Margin
ABBV
4.0%
APLS
2.23%
ROE
ABBV
137.96%
APLS
7.48%
ROA
ABBV
9.59%
APLS
3.53%

Growth

Revenue Growth
ABBV
9.1%
APLS
-5.9%
Earnings Growth
ABBV
-88.7%
APLS
--

Financial Health

Debt/Equity
ABBV
--
APLS
1.28
Current Ratio
ABBV
0.72
APLS
3.14
Quick Ratio
ABBV
0.47
APLS
2.59

Dividends

Dividend Yield
ABBV
3.05%
APLS
--
Payout Ratio
ABBV
490.15%
APLS
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
APLS BEARISH

APLS exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile foundation despite some positive gross margins and cash reserves. The company is unprofitable with negative operating margins and declining revenue, while insider selling activity and a bearish technical trend signal pessimism. Although the Graham Number ($3.44) and intrinsic value ($1.26) suggest deep undervaluation, the current price of $18.94 reflects high growth expectations that are not supported by fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given a debt/equity ratio of 1.28 and negative earnings. Analysts recommend 'buy' with a target of $33.60, but this optimism appears disconnected from deteriorating operational and financial trends.

Strengths
High gross margin of 60.34% indicates strong pricing power or low production costs
Current ratio of 3.14 and quick ratio of 2.59 suggest strong short-term liquidity
Positive earnings surprises in 2 out of the last 4 quarters (average +29.25%) show potential for upside in earnings execution
Risks
Piotroski F-Score of 4/9 indicates weak financial health and deteriorating fundamentals
Negative operating margin (-25.58%) and declining revenue (YoY -5.90%) signal ongoing operational inefficiencies
Insiders sold $1.47M worth of shares in the last 6 months with no buys, signaling lack of confidence

Compare Another Pair

ABBV vs APLS: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Apellis Pharmaceuticals, Inc. (APLS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile